Sermorelin prompts the pituitary to release growth hormone. Historically, approved products under the Geref name were used in children with growth hormone deficiency and as a diagnostic agent to assess pituitary growth-hormone secretion. FDA subsequently withdrew approval of those discontinued products.
That history is often left out. Sermorelin now reaches patients mainly as a compounded preparation, marketed for sleep, recovery, body composition, muscle gain and aging. Those are not approved indications, and a compounded preparation is not FDA-approved for anything.
Being current about emerging options means being able to explain exactly this: what was approved, for whom, whether it still exists as an approved product, and what human evidence supports the use being proposed. Where that evidence is thin, the right thing to do is say so.
Risks and limitations
- Historical approvals were for pediatric growth hormone deficiency and diagnostic use; those products were discontinued.
- Compounded sermorelin is not FDA-approved for longevity, muscle gain, sleep, recovery or aging.
- Human outcome evidence for the marketed anti-aging uses is limited.
- Compounded product quality depends on the compounder and is not pre-market reviewed by FDA.
- This page does not state which therapies MMI offers.